Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer

Figures & data

Figure 1. Plain language summary.

Figure 2. ZONA IC model structure and analysis framework.

HZ = herpes zoster; IC = immunocompromised; PHN = postherpetic neuralgia; ZONA = ZOster ecoNomic Analysis.

Vaccination may or may not occur in the no HZ health state, depending on the modeled strategy.

Figure 3. Number needed to vaccinate to avoid one HZ case and one PHN case, by population.

HSCT = hematopoietic stem cell transplant; HZ = herpes zoster; IC = immunocompromised; NNV = number needed to vaccinate; PHN = postherpetic neuralgia.

Table 1. Results for selected cancer populations vaccinated with RZV versus no vaccine.

Outcomes for RZV versus no vaccine	HSCT	Breast cancer	Hodgkin’s lymphoma
Cases avoided during 30-year time horizon
HZ cases	2,297	38,068	848
PHN cases	422	3,184	93
Complication cases	271	3,812	80
Ocular	81	1,360	28
Neurological	41	1,024	14
Cutaneous	129	905	30
Other non-pain	20	521	7
Cases avoided during IC period
HZ cases	2,210	8,435	438
PHN cases	403	1,095	63
Complication cases	265	1,012	52
Ocular	78	300	15
Neurological	39	149	7
Cutaneous	127	487	25
Other non-pain	19	75	3
QALYs gained	109	506	17

HSCT = hematopoietic stem cell transplant; HZ = herpes zoster; IC = immunocompromised; PHN = postherpetic neuralgia; QALYs = quality-adjusted life years; RZV = recombinant zoster vaccine.

Figure 4. Probabilistic sensitivity analysis for HSCT population.

HSCT = hematopoietic stem cell transplant; HZ = herpes zoster.